Does Valoctocogene Roxaparvovec Rvox Interact with Efavirenz?
Valoctocogene Roxaparvovec Rvox and Efavirenz have a major drug interaction according to U.S. FDA drug labeling data. One HIV-positive patient experienced asymptomatic elevations of ALT, AST, GGT (>5.0 × ULN) and serum bilirubin (>ULN to 1.5 × ULN) at Week 4. Reaction resolved after changing antiretroviral regimen to exclude efavirenz. The mechanism involves efavirenz suppresses factor viii transcription independent of hepatotoxicity. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Efavirenz Class
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Valoctocogene Roxaparvovec Rvox and Efavirenz occurs because efavirenz suppresses factor viii transcription independent of hepatotoxicity. Clinically, this means one hiv-positive patient experienced asymptomatic elevations of alt, ast, ggt (>5.0 × uln) and serum bilirubin (>uln to 1.5 × uln) at week 4. reaction resolved after changing antiretroviral regimen to exclude efavirenz. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Valoctocogene Roxaparvovec Rvox and your doctor is considering prescribing Efavirenz (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider